Feature | December 28, 2012

American College of Cardiology Names Top Cardiovascular Stories of 2012

Top Cardiovascular Stories 2012 Software CT angiography Heart Valve Repair

December 28, 2012 — The past year in cardiology has continued to see progress and innovation in medicine. As the year comes to an end, the American College of Cardiology (ACC) identified some of the top cardiovascular stories of 2012.

Electronic applications moved into the doctor’s office. iPhone apps were introduced to generate electrocardiograms (ECGs), help diagnose atrial fibrillation or help patients quit smoking, while the ACC’s CardioSmart Explorer app was introduced to provide animated 3-D heart images to help cardiologists explain conditions to their patients.

The Choosing Wisely campaign got national attention. Medical societies, including the ACC, identified over-performed procedures that physicians and patients should discuss together. The campaign was meant to help open the discussion between patients and providers about the costs, risks and benefits of certain procedures.

The Affordable Care Act upheld. In June, the U.S. Supreme Court upheld the majority of the Affordable Care Act, with the court ruling the individual mandate was constitutional as a tax.

Bariatric surgery identified as tool for controlling diabetes in some. A new study, presented at ACC.12 in Chicago, found bariatric surgery with medical therapy was better than intensive medical therapy alone for controlling blood sugar in obese patients with type 2 diabetes.

The U.S Food and Drug Administration (FDA) expanded approved uses for transcatheter aortic valve replacement (TAVR). The FDA approved TAVR for high-risk patients. Previously, the FDA had approved the treatment for only inoperable patients.

Warfarin alternative approved. FDA approval was also given to rivaroxaban, a warfarin alternative, to treat pulmonary embolism and deep vein thrombosis.

Surgery identified as better than stents for some patients. Coronary artery bypass grafting (CABG) was shown in a study to be better than percutaneous coronary intervention (PCI) for treatment of patients with diabetes and multi-vessel coronary artery disease.

New cholesterol-lowering drug showed potential. PCSK9 inhibitors demonstrated success in significantly lowering LDL cholesterol. This development opens the door to promising new techniques and medicines for lowering cholesterol.

• Generic drugs impacted consumers. Generic forms of cholesterol-lowering statin Lipitor were marketed in 2012, and the patent for Plavix expired, leading to the FDA approval of generic alternatives.

For more information: www.cardiosource.org/ACC

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init